After oral administration gestodene is rapidly and completely absorbed, its maximum serum concentration equal to 3.5 ng / ml, is reached in about 1 hour. Bioavailability is about 99%. Distribution . Gestodene binds serum albumin and globulin binding sex steroids . The free form is only about 1.3% of the total serum concentration; about 69% – specifically linked . Induction of the synthesis of boldenone acetate boldenone propionate recipe ethinylestradiol influences the binding of gestodene with whey protein. Metabolism . Gestodene is almost completely metabolized. Serum clearance of approximately 0.8 ml / min / kg. Excretion. Gestodene content undergoes biphasic serum decrease.
The half-life in the terminal phase is about 12 h unmodified form gestodene is not displayed, but only in the form of metabolites which are excreted in the urine and bile in a ratio of about 6: 4. With a half-life of about 24 hours. The equilibrium concentration . Effect on the pharmacokinetics of gestodene serum. As a result, the level of daily dosing substance in serum increased about four times during the second half of a treatment cycle. • Ethinylestradiol Absorption . After oral administration, ethinylestradiol is rapidly and completely absorbed. Maximum serum concentration equal to approximately 65 pg / ml, is reached in 1-2 hours. During the suction and the first passage through the liver is metabolized ethinylestradiol, whereby its oral bioavailability averages about 45%. The distribution . Ethinyl estradiol is almost full (about 98%), while non-specifically binds to albumin. Ethinyl estradiol induces the synthesis . The apparent volume of distribution of ethinylestradiol is 2,8-8,6 l / kg. Metabolism . Ethinylestradiol undergoes conjugation presistemna as mucosa of the small intestine and in the liver. The main route of metabolism of aromatics hydroxylation. The rate of clearance from the blood plasma of 2,3-7 ml / min / kg. Excretion . The decrease in serum concentrations of ethinyl estradiol is biphasic; The first phase is characterized by a half-life of about 1 hour, the second – 10-20 hours. In an unmodified form of the organism is not displayed. Ethinylestradiol metabolites are excreted in the urine and bile in a ratio of 4: 6 with a half-life of about 24 hours. The equilibrium concentration . Equilibrium concentration is achieved in about one week.
Femoden should not be applied if any of the conditions listed below. If any of these conditions develop for the first time in patients receiving the drug should be boldenone acetate boldenone propionate recipe immediately repealed.
- Thrombosis (venous and arterial) and thromboembolism present or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident).
- Conditions prior thrombosis (including transient ischemic attack, angina pectoris) now or in history.
- Migraine with focal neurological symptoms in the present or in history
- Diabetes mellitus with vascular complications.
- Multiple or severe venous or arterial thrombosis risk factors, including valvular lesions, cardiac arrhythmia, vascular diseases of the brain or coronary arteries; uncontrolled hypertension.
- Pancreatitis with severe hypertriglyceridemia now or in history.
- Liver failure and severe liver disease (as long as liver function tests have not come back to normal).
- Liver tumors (benign or malignant) now or in history.
- Identified hormone malignancies (including genital or mammary glands) or are suspected.
- Vaginal bleeding of unknown origin.
- Pregnancy or suspected it.
- The period of lactation.
- Hypersensitivity to any component of the drug Femoden
Application with caution
if any of the conditions / risk factors mentioned below are currently available, you should carefully weigh the potential risks and expected benefits of the use of combined oral contraceptives in each individual case:
- Risk factors for thrombosis and thromboembolism: smoking, thrombosis, myocardial infarction or cerebrovascular accident at a young age in any of the next of kin; obesity; dislipoproteinemia (eg, hypertension, migraine, valvular heart disease, cardiac arrhythmias, prolonged immobilization, major surgery, major trauma
- Other diseases in which may occur peripheral circulatory disorders: diabetes; systemic lupus erythematosus; hemolytic uremic syndrome; Crohn’s boldenone acetate boldenone propionate recipe disease and ulcerative colitis; sickle cell anemia; and phlebitis of superficial veins
- liver disease
- Diseases caused or aggravated first time during pregnancy, or on the background of the previous use of sex hormones (eg, jaundice, cholestasis, gallbladder disease, otosclerosis with hearing impairment, porphyria, herpes gestationis, Sydenham’s chorea)